[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [HEALTH]

2 clusters · 4 sources · 9 days · First seen · Last updated

Triple-negative breast cancer research developments

Overview

Recent research has identified new mechanisms and therapeutic strategies to combat triple-negative breast cancer (TNBC).

Researchers at the National University of Singapore identified a regulatory mechanism called the ‘DP103 master switch’ that drives tumor growth and resistance. Using the drug RX-5902 (Supinoxin) in laboratory models, they were able to deactivate processes within the Wnt signaling pathway, resulting in a 40 to 60 percent reduction in cancer stem cell viability.

In a separate study, researchers at the Medical University of South Carolina developed a ‘one-two-punch’ dual-drug strategy. This method targets the protein lysyl oxidase (LOX) to weaken cancer cells, subsequently using a second drug to block backup survival pathways. In preclinical models, this approach significantly inhibited tumor growth without relying on chemotherapy.

Entities

National University of Singapore · Ozgur Sahin · Medical University of South Carolina Hollings Cancer Center

Timeline

  1. 26 days ago

    [HEALTH] 2 sources
    MUSC researchers develop dual-drug strategy for triple-negative breast cancer

    MUSC Hollings Cancer Center researchers have developed a dual-drug strategy to target triple-negative breast cancer by blocking the LOX protein to create vulnerabilities in chemoresistant cells.

  2. about 1 month ago

    [HEALTH] 2 sources
    National University of Singapore researchers identify breast cancer target

    National University of Singapore researchers identified the DP103 master switch in triple-negative breast cancer and a drug, RX-5902, that can significantly reduce tumor growth and cell viability.

Sources

concept-ophthalmologie.de · genengnews.com · it-boltwise.de · news-medical.net